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Blocking DLL4, a Notch ligand, effectively inhibits
tumor growth by increasing non-functional angiogenesis
and decreasing the cancer stem cell (CSC) population.
Preclinical studies have demonstrated inhibition of
tumor growth by anti-DLL4 treatment and have led us
to enter demcizumab, an anti-DLL4 mAb, into ongoing
clinical trials. Vascular endothelial growth factor A
(VEGF A) also plays a central role in inducing tumor
angiogenesis. VEGF signaling is also involved in recruit-
ing immune suppressive myeloid cells. Therefore, target-
ing VEGF could induce favorable immune responses
against cancer. We developed a bispecific monoclonal
antibody that blocks both DLL4 and VEGF which is in
Phase I clinical trials. In the present study we compare
the impact of anti-DLL4 in combination with anti-VEGF
and anti-DLL4 in combination with anti-VEGF and anti-
Programmed Cell Death Protein 1 (PD1) on anti-tumor
immune responses. Our data demonstrate that the triple
blockade of DLL4-VEGF-PD1 significantly inhibited
tumor growth with more pronounced tumor regression.
Anti-DLL4 treatment reduced IL17 production, an effect
not observed with anti-PD1, blockade of DLL4-VEGF or
DLL4-VEGF-PD1, suggesting that blocking DLL4 alone
and together with VEGF or VEGF and PD1 might have
different mechanisms for regulating immune responses.
Anti-PD1 increased specific CD8+ T cell-mediated IFN-
gamma production while decreasing IL6. Interestingly,
IL2 was increased at the tumor site by blockade of
DLL4-VEGF-PD1 compared to controls. Since IL2 is
required for secondary population expansion of CD8+
memory T cells, increased IL2 in the triple combination
group suggests potential for increased T cell activation,
maintenance and memory T cell function, as compared
to single agent anti-DLL4 and anti-PD1. Memory CD8+
T cell frequencies were increased within the total CD8+
T cell population by DLL4-VEGF-PD1 triple blockade.
Therefore, these results show that co-targeting of DLL4
and VEGF with PD1 might be an effective and durable
anti-cancer therapy in part by promoting anti-tumor
immune responses and inhibiting pro-tumor immune
responses.
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